| Deleyrolle, Phuong |
| Completed | 2 | 175 | US | pp65-shLAMP DC with GM-CSF, pp65-shLAMP mRNA DCs with GM-CSF, unpulsed PBMC and saline, Peripheral Blood Mononuclear Cells, Td, Tetanus and Diphtheria Toxoid, Saline, Normal Saline, pp65-flLAMP DC with GM-CSF, pp65-flLAMP mRNA DCs with GM-CSF | University of Florida, National Cancer Institute (NCI) | Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM | 11/23 | 11/23 | | |
ADAGiO, NCT06254326: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients |
|
|
| Active, not recruiting | 1 | 12 | US | TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine | University of Florida, Oligo Nation, Inc | Recurrent Oligodendroglioma, Progressive Oligodendroglioma | 12/27 | 06/28 | | |
NCT06389591: RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) |
|
|
| Active, not recruiting | 1 | 24 | US | pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) | University of Florida, National Cancer Institute (NCI) | Recurrent Glioblastoma | 12/27 | 12/28 | | |
IMPACT, NCT05353530: Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma |
|
|
| Recruiting | 1 | 18 | US | Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, 8R-70CAR T cells | University of Florida, United States Department of Defense, AM Rosen Foundation | Glioblastoma Multiforme, Glioblastoma | 12/27 | 12/42 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
| Woodworth, Graeme F |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
NCT04417088: Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy |
|
|
| Active, not recruiting | 1/2 | 30 | US | Carboplatin, Exablate BBBD, Exablate Neuro | InSightec | Recurrent Glioblastoma | 12/23 | 07/24 | | |
NCT03551249: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption |
|
|
| Completed | N/A | 20 | US | Focused ultrasound (FUS), ExAblate, Type 2 | InSightec | Glioma, Glioblastoma | 12/23 | 12/23 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Recruiting | N/A | 32 | US | Procedure: LITT, Laser Interstitial thermal therapy, Hypo-Fractionated Radiation Therapy | University of Maryland, Baltimore, Keep Punching Foundation | Glioblastoma, Brain Tumor, Glioma, Neoplasms | 12/25 | 12/26 | | |
NCT04699773: LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) |
|
|
| Recruiting | N/A | 32 | US | LITT, Laser Interstitial thermal therapy, Hypofractionated Radiation Therapy | University of Maryland, Baltimore, Keep Punching Foundation | Glioma, Glioblastoma, Brain Tumor | 02/25 | 12/27 | | |
| Henry, Kaitlyn |
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
|
|
| Recruiting | 3 | 20 | Canada, US, RoW | Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab | InSightec | Brain Tumor | 06/24 | 12/24 | | |
| Terminated | 2 | 1 | US | Pioglitazone 15mg | University of Maryland, Baltimore, Nico Corporation | Intracerebral Haemorrhage, Intraventricular | 09/24 | 09/24 | | |
NCT04417088: Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy |
|
|
| Active, not recruiting | 1/2 | 30 | US | Carboplatin, Exablate BBBD, Exablate Neuro | InSightec | Recurrent Glioblastoma | 12/23 | 07/24 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT04579692: MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia |
|
|
| Recruiting | N/A | 10 | US | ExAblate Transcranial treatment, The ExAblate® MR guided focused ultrasound system | University of Maryland, Baltimore, Focused Ultrasound Foundation, InSightec | Trigeminal Neuralgia | 06/25 | 06/25 | | |
| Recruiting | N/A | 10 | US | ExAblate Transcranial treatment, The ExAblate® MR guided focused ultrasound system | University of Maryland, Baltimore, Focused Ultrasound Foundation, InSightec | Task-Specific Focal Dystonia | 06/27 | 06/28 | | |
| Recruiting | N/A | 1500 | Canada, US | No Treatment Given | Robert G. Grossman, MD, Christopher Reeve Paralysis Foundation, The Methodist Hospital Research Institute, The University of Texas Health Science Center, Houston, University of Virginia, University of Louisville, University of Toronto, University of Maryland, Baltimore, Walter Reed National Military Medical Center, Thomas Jefferson University, University of Miami, Brooke Army Medical Center, Louisiana State University Health Sciences Center in New Orleans, Vanderbilt University Medical Center, Medical College of Wisconsin, Duke University | Spinal Cord Injury | 07/25 | 07/28 | | |
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device |
|
|
| Recruiting | N/A | 180 | US | WEB | Microvention-Terumo, Inc. | Wide Neck Bifurcation Intracranial Aneurysms | 12/25 | 12/29 | | |
NCT05539196: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications |
|
|
| Recruiting | N/A | 60 | Japan, US | Exablate Pallidotomy, Unilateral | InSightec | Movement Disorders, Neurology, Parkinsons Disease | 07/29 | 07/29 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
| Santana, Daylen |
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects |
|
|
| Recruiting | 1/2 | 98 | US | VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine | VBI Vaccines Inc. | Glioblastoma Multiforme | 07/25 | 08/25 | | |
TUTOR, NCT05553522: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer |
|
|
| Recruiting | 1 | 40 | US | Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine | Baptist Health South Florida, Pfizer | Brain Metastases, HER2-positive Breast Cancer | 02/28 | 02/29 | | |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
| Hilliard, Justin |
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors |
|
|
| Recruiting | N/A | 57 | Canada, US | Focused Ultrasound (Exablate Model 4000) | InSightec | Glioblastoma, Glioma, Liquid Biopsy | 12/24 | 03/25 | | |
NCT03671889: ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | N/A | 150 | US | Blood Brain Barrier (BBB) Disruption, ExAblate Neuro | InSightec | Alzheimer Disease | 12/25 | 12/25 | | |
